Phase 3 Prostate Cancer Trial, Recruiting (NCT07209878)

Phase 3 Prostate Cancer Trial, Recruiting NCT07209878 Sponsor: First Affiliated Hospital of Fujian Medical University Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07209878 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with prostate cancer (a specific type called adenocarcinoma), confirmed by a biopsy
People who have not received any cancer treatment before the PET scan involved in this trial
People who are willing and able to follow all the requirements of the trial, and who have signed a consent form agreeing to take part
People who have surgery to remove the prostate gland already scheduled to take place within 28 days after the PET scan

Who may not be able to join:

People who have been diagnosed with any other type of cancer
People who have a medical condition or other circumstances that, in the opinion of the trial doctor, could affect the reliability of the results or the ability to complete the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Weibign Miao, MD, First Affiliated Hospital of Fujian Medical University

Phone: 86-0591-87981618

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07209878

Sponsor: First Affiliated Hospital of Fujian Medical University

Phase: Phase 3

Status: Recruiting

Condition: Prostate Cancer

Trial contact: 86-0591-87981618

More information: https://clinicaltrials.gov/study/NCT07209878

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with prostate cancer (a specific type called adenocarcinoma), confirmed by a biopsy
People who have not received any cancer treatment before the PET scan involved in this trial
People who are willing and able to follow all the requirements of the trial, and who have signed a consent form agreeing to take part
People who have surgery to remove the prostate gland already scheduled to take place within 28 days after the PET scan

Who may not be able to join:

People who have been diagnosed with any other type of cancer
People who have a medical condition or other circumstances that, in the opinion of the trial doctor, could affect the reliability of the results or the ability to complete the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

First Affiliated Hospital of Fujian Medical University

Registry

ClinicalTrials.gov

Start date

10 January 2020

Est. completion

31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Sensitivity of 68Ga-PSMA-11 Imaging to Detect Intraprostatic Tumors Relative to Histopathology in newly diagnosed, treatment-naive Prostate Cacner Participants; Specificity of 68Ga-PSMA-11 PET Imaging to Detect Intraprostatic Tumors Relative to Histopathology in newly diagnosed, treatment-naive Prostate Cacner Participants

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov